WCN26-6851 A RANDOMIZED CONTROLLED TRIAL OF ALLOPURINOL FOR CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: BASELINE CHARACTERISTICS OF THE STUDY POPULATION

Read full text Summarise with VIRAT
Authors: Komal k Sharma, Piyush Mohania, Kanchan Thakur, Vivek Kumar, Ashok Yadav, Harbir Singh Kohli, Vivekanand Jha
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Hyperuricemia has been associated with adverse cardiovascular outcomes in patients with chronic kidney disease (CKD). Although uric acid lowering therapy has shown short-term cardiovascular benefits, long-term effects remain uncertain. Previous studies have shown ineffectiveness of allopurinol in slowing CKD progression, though they were not primarily designed to assess cardiovascular endpoints. This study aimed to evaluate whether allopurinol, compared with placebo, reduces the risk of major adverse cardiovascular events (MACE) in CKD patients.

Fields of Study & Subjects

Gout Hyperuricemia Uric Acid Chronic Kidney Disease and Diabetes Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104374–104374
Publication date
25 March 2026
Language
EN